RECRUITING

Single Dose Monoaminergic Drive in Stroke

Description

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.

Conditions

Stroke
Talk to us

Related Conditions:

Stroke

Study Overview

On this page

Study Details

Study overview

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.

Single Dose Monoaminergic Drive in Stroke

Single Dose Monoaminergic Drive in Stroke

Condition
Stroke
Intervention / Treatment

-

Contacts and Locations

Chicago

Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment
  • * Age between 18-80
  • * Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 15-45/66, Chedoke McMaster Stroke Assessment Hand section \<=4)
  • * Ability to communicate, understand, and provide informed consent
  • * Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension
  • * MRI compatible
  • * Intact skin on the hemiparetic arm
  • * Ability to sit for three hours.
  • * Motor or sensory impairment in the non-affected limb (FMA\<66, filament \>3.6)
  • * Any brainstem and/or cerebellar lesion
  • * untreated cardiovascular disease
  • * History of neurologic disorder other than stroke that affects the arms
  • * Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale
  • * Current use of a pacemaker
  • * History of seizure
  • * Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol/alcohol injections \<12 months before participation
  • * Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes
  • * Current participation in any experimental rehabilitation or drug studies
  • * Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity
  • * pregnant women or women who are nursing.

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Northwestern University,

Julius Dewald, DPT, PhD, PRINCIPAL_INVESTIGATOR, Northwestern University

Jun Yao, PhD, PRINCIPAL_INVESTIGATOR, Northwestern University

Study Record Dates

2029-07-31